A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples